Unclear on the concept
The whole point of the Alltrials.net campaign is to prevent selective publication of clinical trial results. The problem is that drug companies (and everyone else) publish only about half of their trials and are more likely to publish results if they are positive, distorting the available evidence. The only fix is not to let them be selective.
Roche has responded to the campaign by saying it will set up a panel to approve requests for access to anonymised patient data. That’s nice, and it will be helpful for certain types of research, but it completely misses the point of the AllTrials campaign.
As Tracey Brown, of the British organisation Sense about Science, comments: “Which bit of All and Trials do they not understand?”
Thomas Lumley (@tslumley) is Professor of Biostatistics at the University of Auckland. His research interests include semiparametric models, survey sampling, statistical computing, foundations of statistics, and whatever methodological problems his medical collaborators come up with. See all posts by Thomas Lumley »